";s:4:"text";s:5816:" informational and educational purposes only. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcveGVsb2RhLWNhcGVjaXRhYmluZS0zNDIyMTE=
Cautions.
Monitor closelyHypersensitivity to capecitabine or fluorouracil (5-FU)May result in bleeding, death; monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordinglyDiarrhea may be severe; interrupt capecitabine treatment immediately until diarrhea resolves or decreases to grade 1; recommend standard antidiarrheal treatmentsMay cause cardiomyopathy and acute decreases in LVEFIncreased risk of severe or fatal adverse reactions in patients with low or absent dihydropyrimidine dehydrogenase (DPD) activity; withhold or permanently discontinue capecitabine in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity; no capecitabine dose has been proven safe in patients with absent DPD activityInterrupt capecitabine treatment until dehydration is corrected; potential risk of acute renal failure secondary to dehydration; monitor and correct dehydrationCan cause fetal harm; advise women of the potential risk to the fetusBased on animal studies, therapy may impair fertility in females and males of reproductive potentialSevere mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), reported; discontinue therapy in patients who experience a severe mucocutaneous reaction during treatment; capecitabine may induce hand-and-foot syndrome; interrupt capecitabine treatment until hand-and-foot syndrome event resolves or decreases in intensity; persistent or severe hand-and-foot syndrome can eventually lead to loss of fingerprintsIf hypervilirubinemia occurs, interrupt therapy immediately until it resolves or decreases in intensityDo not treat patients with neutrophil counts <1.5 x 10^9;/L or thrombocyte counts <100 x 10^9;/L; if grade 3-4 neutropenia or thrombocytopenia occurs, stop therapy until condition resolvesBased on findings in animal reproduction studies and its mechanism of action, therapy can cause fetal harm when administered to a pregnant; limited available human data are not sufficient to inform drug-associated risk during pregnancyIn animal reproduction studies, therapy in pregnant animals during period of organogenesis caused embryo lethality and teratogenicity in mice and embryo lethality in monkeys at 0.2 and 0.6 times, respectively, the exposure (AUC) in patientsPregnancy testing is recommended for females of reproductive potential prior to initiating therapyThere is no information regarding presence in human milk, or effects on milk production or breast-fed infant; drug metabolites were present in milk of lactating mice; because of potential for serious adverse reactions from exposure in breast-fed infants, advise women not to breastfeed during therapy and for 2 weeks after final doseA: Generally acceptable. (14, 15) From the community: “I have been on Xeloda since January. Risk factors include >60 years of age and cancer.
/viewarticle/906068
provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.
Hair thinning may begin after the first or second capecitabine treatment.
1,250 mg/m² PO BID x 2 weeks, followed by 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks) Metastatic, resistant to paclitaxel, anthracyclinesCombo therapy with Docetaxel: 1250 m² PO BID for 2 weeks q3Weeks plus docetaxel 75 mg/m² 1 hour IV infusion q3WeeksDosage may need to be individualized to optimize patient managementCapecitabine may increase the anticoagulant effects of warfarin increasing the INR several days up to several months after initiating capecitabine or within one month after stopping the therapy. Your list will be saved and can be edited at any time.The above information is provided for general
Contact the applicable plan
Drugs
Thinned out hair usually grows back once treatment is over. News
Liver Dose Adjustments
encoded search term (capecitabine (Xeloda)) and capecitabine (Xeloda) EMA Panel Recommends DPD Testing Prior to Fluorouracil TreatmentOnc Daily: DPD Testing Advised, Free Parking at Cancer CentersEurope Recommends DPD Testing BeforeIV Fluorouracil Hematology-Oncology Guidelines: 2017 Midyear ReviewTime to Stop Pressuring Women on Screening Mammography?Mid-Career Oncologist Cites Harassment, Leaves Top Center Mammography Starting at 40 Cuts Risk of Breast Cancer Death 'Groundbreaking' Cancer Drug Recycling at Major US CenterEMA Starts Review on DPD Testing Before ChemotherapyTNBC Study of Capecitabine Mostly Disappoints, With One ExceptionShare cases and questions with Physicians on Medscape consult. Because of this complication, interruption of medication, depending on an individual's … Take the tablets up to 30 minutes after a meal, with plenty of water.
You might have two different strengths of tablets to make up the correct dose.